drugset
drugset / Trial / NCT05753852

Open Label Extension of TUDCA-ALS Study

NCT05753852 ↗

Phase 3 Unknown 184 enrolled Humanitas Mirasole SpA Bruschettini S.r.l. · collabIstituto Superiore di Sanità · collabKU Leuven · collabMotor Neurone Disease Association · collabUMC Utrecht · collabUniversity Hospital, Tours · collabUniversity of Dublin, Trinity College · collabUniversity of Sheffield · collabUniversity of Ulm · collab
NaSingle-groupOpen-labelTreatment

Summary

This study will provide extended access to patients and assess longer-term outcomes on patients who have completed the TUDCA-ALS study.

Timeline

Start
2021-10-25
Primary completion
2025-03-31
Completion
2025-03-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Taurursodiol Small molecule 1 g Oral

Indications

amyotrophic lateral sclerosis